Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

THE TRUTH ABOUT: 28 - Caught on Camera

Benzinga's Top Ratings Upgrades, Downgrades For June 7, 2022

The Daily Biotech Pulse: Veru Seeks Emergency Use Nod For COVID-19 Therapy, Vincerx Cuts Workforce, Moderna Starts Dosing In Flu Vaccine Study

The Daily Biotech Pulse: Veru Seeks Emergency Use Nod For COVID-19 Therapy, Vincerx Cuts Workforce, Moderna Starts Dosing In Flu Vaccine Study

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga's Top Ratings Upgrades, Downgrades For May 31, 2022

Benzinga's Top Ratings Upgrades, Downgrades For May 31, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Shortage of diabetes medication Ozempic after TikTok users promote drug for weight loss

TGA urges GPs to limit prescriptions to approved use for diabetes management amid surge in off-label demand

The Guardian - AU

Peering Into Novo Nordisk's Recent Short Interest

Novo Nordisk's (NYSE:NVO) short percent of float has fallen 20.0% since its last report. The company recently reported that it has 2.07 million shares sold short, which is 0.12% of all regular shares that are available for trading.

Here's How Much You Would Have Made Owning Novo Nordisk Stock In The Last 10 Years

Novo Nordisk (NYSE:NVO) has outperformed the market over the past 10 years by 2.43% on an annualized basis producing an average annual return of 14.2%. Currently, Novo Nordisk has a market capitalization of $253.71 billion.

If You Invested $100 In Novo Nordisk 10 Years Ago, Here's How Much You Would Have Today

Novo Nordisk (NYSE:NVO) has outperformed the market over the past 10 years by 2.28% on an annualized basis producing an average annual return of 14.59%. Currently, Novo Nordisk has a market capitalization of $268.66 billion.

inkl

Read news from The Economist, FT, and more,
with one subscription

Why Novo Nordisk Shares Are Trading Higher Today

Why Novo Nordisk Shares Are Trading Higher Today

The FDA has approved Novo Nordisk A/S's (NYSE:NVO) 2.0 mg dose of Ozempic (once-weekly semaglutide subcutaneous injection), a glucagon-like peptide-1 (GLP-1) analog for type 2 diabetes. Ozempic is now approved in the US at 0.5 mg,1.0 mg, and 2.0 mg doses to treat type 2 diabetes in adults. Further, Ozempic is indicated to…

$1000 Invested In Novo Nordisk 10 Years Ago Would Be Worth This Much

$1000 Invested In Novo Nordisk 10 Years Ago Would Be Worth This Much

Novo Nordisk (NYSE:NVO) has outperformed the market over the past 10 years by 2.52% on an annualized basis producing an average annual return of 14.65%. Currently, Novo Nordisk has a market capitalization of $250.29 billion.

Novo Nordisk Doubles 2025 Sales Target On Strong Wegovy Demand

Novo Nordisk Doubles 2025 Sales Target On Strong Wegovy Demand

Novo Nordisk A/S (NYSE: NVO) has more than doubled its target for sales of obesity drugs by 2025 after overwhelming demand for its new Wegovy drug.

Novo Nordisk Posts Upbeat Q4 Earnings, Expects Obesity Drug Shortages May Soon Be Resolved

Novo Nordisk Posts Upbeat Q4 Earnings, Expects Obesity Drug Shortages May Soon Be Resolved

Novo Nordisk A/S (NYSE: NVO)

Novo Nordisk: Q4 Earnings Insights

Novo Nordisk: Q4 Earnings Insights

Novo Nordisk (NYSE:NVO) reported its Q4 earnings results on Wednesday, February 2, 2022 at 01:30 AM. Here's what investors need to know about the announcement.

1 … 25 26 27 28

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Occidental Petroleum

B of A Securities

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

397,062 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play